Excessive fluid accumulation during stem cell mobilization: A novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients

Blood

Volumn 106, Issue 10, 2005, Pages 3353-3357

  Leung, Nelson ^a   Leung, Tessa R ^b   Cha, Stephen S ^b   Dispenzieri, Angela ^b   Lacy, Martha Q ^b   Gertz, Morie A ^b  

^a MAYO CLINIC ROCHESTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; SERUM ALBUMIN;

ADULT; AMYLOIDOSIS; ARTICLE; CAUSE OF DEATH; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THICKNESS; TREATMENT OUTCOME; WEIGHT GAIN; WHOLE BODY RADIATION;

EID: 27744488826     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1206     Document Type: Article

References (25)

1. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [comment]. N Engl J Med. 1997;336:1202-1207.
2. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978;52:818-827.
3. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290-298.
4. Kyle RA, Greipp PR, Garton JP, Gertz MA. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med. 1985;79:708-716.
5. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol. 1999;16:104-109.
6. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. 1999;17:262-267.
7. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
8. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113:549-555.
9. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960-3963.
10. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004;33:271-277.
11. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766-769.
12. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
13. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000;26:963-969.
14. Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis. 1997;30:646-652.
15. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
16. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881-1887.
17. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445.
18. Rechner I, Brito-Babapulle F, Fielden J. Systemic capillary leak syndrome after granulocyte colonystimulating factor (G-CSF). Hematol J. 2003;4:54-56.
19. Akasheh M, Eastwood D, Vesole DH. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocytecolony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF). Bone Marrow Transplant. 2003;31:113-116.
20. de Azevedo AM, Goldberg Tabak D. Life-threatening capillary leak syndrome after G-CSF mobilization and collection of peripheral blood progenitor cells for allogeneic transplantation. Bone Marrow Transplant. 2001;28:311-312.
21. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf. 1995;13:371-406.
22. Gertz MA, Lacy MQ, Bjornsson J, Litzow MR. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res. 2000;9:635-643.
23. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
24. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936-2938.
25. Leung N, Leung TR, Dispenzieri A, Lacy MQ, Gertz MA. Excessive weight gain during mobilization increases first year mortality following high dose therapy and stem cell transplantation in patients with primary systemic amyloidosis [abstract]. Blood. 2004;104:269a.